Finding a 'Win-Win-Win Situation'

Dr. Holger Franke, head of Technical Department, Klaus F. Meyer
Dr. Holger Franke, head of Technical Department, Klaus F. Meyer

What kind of growth do you aspire to in the next few years; in which sectors, markets or regions do you see significant growth opportunities?

Klaus F. Meyer aspires to an organic growth in the next years. We are focusing in the European markets as well as emerging markets, especially China, India and Russia.

Our main target markets are pharma and agro chemicals. Especially in the latter one, we expect rising demands for our products because of strong needs for agricultural chemicals in the world.

How do you intend to implement these plans and seize these opportunities?

Together with our costumers we are running projects for new products and new developments. Having good relationships with our main costumers as well as our main producers, we see ourselves as an interface for both of them.

We have already identified some new possibilities, which we discuss with both sides to get a powerful win-win-win situation for all three participating partners.

 

 

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.